Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CLK2 | P49760 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2075811 | 0.88 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL20451992 | 0.88 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4163037 | 0.84 | ALDH1A1 (0.66) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL6362765 | 0.82 | ALDH1A1 (0.49) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL2075032 | 0.81 | ALDH1A1 (0.59) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL15525147 | 0.81 | ALDH1A1 (0.59) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL15525132 | 0.81 | ALDH1A1 (0.59) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4167891 | 0.80 | NPC1 (0.71) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4164804 | 0.78 | RAB9A (0.63) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4172293 | 0.77 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427627-B2 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2008-09-23 | — | — | US | disclosed |
| US-7388015-B2 | N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2008-06-17 | — | — | US | disclosed |
| EP-1760082-A1 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as anti-proliferative compounds | Cyclacel Limited (GB) | 2007-03-07 | — | — | EP | disclosed |
| EP-1430051-B1 | N-(4-(4-METHYLTHIAZOL-5-YL)PYRIMIDIN-2-YL)-N-PHENYLAMINES AS ANTIPROLIFERATIVE COMPOUNDS | CYCLACEL LTD (GB) | 2006-12-27 | — | — | EP | disclosed |
| US-20060199830-A1 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2006-09-07 | — | — | US | disclosed |
| US-20050288307-A1 | Anti-viral compounds | CYCLACEL LIMITED (GB) | 2005-12-29 | — | — | US | disclosed |
| US-20040259894-A1 | N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259894-A1 | N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CDK4, CDK2, CDKL4 | ALDH1A1 2719/4885NPC1 3372/4885RAB9A 4076/4885 |
| US-20060199830-A1 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CDK4, CDK2, CCNI | ALDH1A1 2858/4885NPC1 3372/4885RAB9A 4034/4885 |
| US-20050288307-A1 | Anti-viral compounds | MAVS, HAVCR2, EIF2AK2 | ALDH1A1 2550/4885NPC1 525/4885RAB9A 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.